Search Results

1 - 2 of 2 items :

  • pharmacokinetics x
  • Rheumatology x
  • Internal Medicine x
  • Clinical Medicine x
  • Gastroenterology x
Clear All
A comparison of short-term therapeutic efficacy between infliximab and tacrolimus for moderate to severe ulcerative colitis

. VOIOSU T, BENGUŞ A, BĂLĂNESCU P, DINU R, VOIOSU A, BĂICUŞ C et al. Rapid fecal calprotectin testing predicts mucosal healing better than C-reactive protein and Serum tumor necrosis factor α in patients with ulcerative colitis. Rom J Intern Med. 2015; 53(3):253-60. 18. DOTAN I, RON Y, YANAI H, BECKER S, FISHMAN S, YAHAV L et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis. 2014; 20(12):2247-59. 19. BRANDSE JF, MATHÔT RA, VAN

Open access
The frequency of bone fractures among patients with chronic kidney disease not on dialysis: two-year follow-up

., AKITA W., KUYAMA T., TAKADA S., ASAI T., et al. Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients – a single-center cohort study. Nephrol Dial Transplant 2012; 27 :345-51. 27. LIN JH. Bisphosponates: a review of their pharmacokinetic properties . Bone. 1996; 18 (2):75-85. 28. CONTR P., GUARNERI V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimen. The Oncologist.2004; 9 (Suppl 4): 28-37. 29. SHERRARD DJ., HERCZ G., PEI Y

Open access